trial · primary record
MB11 (Proposed Nivolumab Biosimilar)
Advanced (Unresectable or Metastatic) Melanoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 632 |
| Primary completion | 2029-02 |
| Primary endpoint | To demonstrate the Pharmacokinetic (PK) bioequivalence between MB11 and EU/ US-Opdivo. |
| Registry ID | NCT07221734 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:46.122Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07221734
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.